FOXO4-DRI FAQ: common questions answered
An experimental cell-clearing peptide with mouse findings and no established human dose.
Also called: FOXO4 DRI, FOXO4-D-retro-inverso, FOX04-DRI, Proxofim.
Senolytic peptides · Experimental FOXO4-p53 interaction-disrupting peptide · Evidence: Animal studies only.
- Is FOXO4-DRI FDA-approved? No approved product or label found. A prescription or research-only label does not establish FDA approval.
- How do people take it? Under the skin, every other day for six doses. The same author later reports twice-yearly courses; no validated repeat interval. One course, described as 12 days.. Source: reported by users, not an established dose.
- What's the difference between FOXO4-DRI and MOTS-c? FOXO4-DRI: an experimental cell-clearing peptide with mouse findings and no established human dose. MOTS-c: a peptide the body makes; injection benefits and safety remain unproven. Why people pair them: one forum user combined them hoping to improve cell clearance or recovery.
- Can I take it with MOTS-c? One forum user combined them hoping to improve cell clearance or recovery. No human combination trial; claimed synergy is unproven. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Inferred from the S0 rule for drugs without human therapeutic approval; FOXO4-DRI is not explicitly named.
- How long does a mixed vial last? No validated stability, sterility or discard interval after mixing was found.
Related to FOXO4-DRI
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
- Humanin: A peptide the body makes; injection benefits and safety remain unproven.
- Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
- Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Access an unapproved therapeutic good (health practitioners), Therapeutic Goods Administration
- Pulmonary hypertension, NHS
- Supply unlicensed medicinal products (specials), MHRA · MHRA
- Unapproved Drugs, FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.